any studies showing v+o (or other cd20affecting mab) gives superior outcomes to venetoclax alone?

[msbypass4cll]

venetoclax for high risk cll-without enhancing drug

[lankisterguy Volunteer]

Hi msbypass4cll,-

Please insert the string below into a Google search to get a list of all 1,080 postings on our site that mention Venetoclax and clinical trials.

-

site:healthunlocked.com cll support/venetoclax+clinical+trial

-

And the corresponding search that adds Obinutuzumab to the string and gets 580 results:

site:healthunlocked.com cll support/venetoclax+clinical+trial+obinutuzumab

-

It may take some time to peruse them. Each time you see an interesting posting, make certain to also check the box on that page labeled "Related Posts" to see other postings that have similar titles.

-

Len

[Canuck901]

I believe the combo with venetoclax works better, you can see from all the trials on here .

Venetoclax is good at cleaning the bone marrow and the BTK or infusion Gazyva or Rituximab is good at cleaning the blood 🩸

So rhe Venetoclax seem to work much better as a combo as it has synergies with other drugs than monotherapy

That’s my opinion from what I read I am not a doctor 👨‍⚕️

[MrMidnight]

This study showed no particular advantage in adding Rituximab to Venetoclax in pre-treated patients (median of three previous treatments). ashpublications.org/bloodad...

[Canuck901 in reply to MrMidnight]

The Murano trial contradicts this though.

The study indicates , It depends if you were heavily pre-treated. Best responses were ones that were not heavily pre-treated . Plus the sample size of 321 isn’t very large

The combo therapies with Venetoclax are just gaining in popularity and more will be coming

[Smakwater]

msbypass4cll,

When I began treatment in a clinical trial using O+V, the CD20 monoclonal antibody obinutuzumab was used to prior to venetoclax to reduce the risk of tumorlysis that had caused death in some patients previously. The obinutuzumab lowers the lymphocytes mainly in the peripheral blood. The trial showed that the obinutuzumab could be effective in preventing tumorlysis. Although the statistics from these trials may reflect other benefit measures, the purpose of obinutuzumab in the recent FDA approval is to lower the risk of tumorlysis.

There may be other ongoing studies that focus on objectives relative to survival rates, toxicity etc.., however, the currently approved combination still represents the original objective. -

"Of note, monotherapy with obinutuzumab has been reported to be associated with an incidence of TLS of 4.8% in a phase 1/2 trial" < From the publication -

ncbi.nlm.nih.gov/pmc/articl...

Tumorlysis concern is still stated by the drug manufacturer on their information page -

venclexta.com/?cid=ppc_ppd_...

JM